Romidepsin hepatocellular carcinoma suppression in mice is associated with deregulated gene expression of bone morphogenetic protein and Notch signaling pathway components

Afaloniati, Hara; Poutahidis, Theofilos; Giakoustidis, Alexandros; Gargavanis, Athanasios; Giakoustidis, Dimitrios; Angelopoulou, Katerina

doi:10.1007/s11033-020-06089-9

Cited by 4 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apoptosis is a form of programmed cell death that plays an important role in the development and prevention of cancer (Elmore, 2007). Deregulation in the control of apoptosis is often associated with the development of cancer (Afaloniati et al, 2021). The activation of apoptosis in cancer cells is, therefore, a counteractive strategy and many anticancer drugs may exert apoptotic effects in cancer cells (Awan et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

Cytotoxicity and Apoptosis-Induction Potential of Fraction F3 from Fruits of Bersama engleriana (Melanthaceae) against Human Cervical Cancer Cells

Majoumouo¹,

Tincho²,

Morris³

et al. 2022

American Journal of Biochemistry and Biotechnology

View full text Add to dashboard Cite

Cervical cancer is one of the most life-threatening malignancies worldwide, despite intensive research for more efficacious chemotherapeutic agents. Recent efforts geared towards eradicating the scourge of cancer have embodied a major surge of interest in natural products as promising lead molecules in pharmaceutical development and therapeutic translation. Consequently, this study aimed to assess the cytotoxicity of a previously identified plant Fraction (F3) from Bersama engleriana against cervical cancer (HeLa) cells and non-cancerous normal human foreskin fibroblasts (HFF cells). Flow cytometric analysis via Annexin V/PI in HeLa cells was carried out to assess apoptosis induction. We report here the 50% Inhibitory Concentration (IC50) of fraction F3 to be 96.15 µg/mL and a 50% Cytotoxic Concentration (CC50) of 527.4 µg/mL, as well as a Selectivity Index (SI) of 5.48, thus confirming that fraction F3 is relatively non-toxic to the normal cells compared to the cancer cells evaluated. In addition, microscopic observations showed a higher reduction of cells, aggregated with dark color in HeLa cells treated with fraction F3 compared to control (cells only). The Annexin V/PI analysis showed the percentages of apoptotic cells were 4.6±0.05, 7.9±0.9 and 7.6±0.15, respectively, for the control and treatments of cells with 120 and 150 µg/mL fraction F3 in early apoptosis (Annexin V+/PI-) 48 h post-treatment. Percentages of apoptotic cells were 2.1±0.1, 8.9±0.2 and 7.7±0.2, respectively, for control, 120 and 150 µg/mL fraction F3 treatments in late apoptosis (Annexin V+/PI+) after 48 h posttreatment. Nevertheless, a comparison of the lowest percentage inhibition of apoptosis with the highest number of reduced cells observed with fluorescence microscopy suggests that fraction F3 may exert its growth inhibitory action on HeLa cells via another mechanism. The results established that fraction F3 from B. engleriana is a promising source for exploring antitumor activity.

show abstract

Section: Discussionmentioning

confidence: 99%

Cytotoxicity and Apoptosis-Induction Potential of Fraction F3 from Fruits of Bersama engleriana (Melanthaceae) against Human Cervical Cancer Cells

Majoumouo¹,

Tincho²,

Morris³

et al. 2022

American Journal of Biochemistry and Biotechnology

View full text Add to dashboard Cite

show abstract

“…Similarly, in BALB/c nude mice and NOD/SCID mice, quisinostat (3 and 10 mg/kg/day, i.p) has been used to treat tongue and esophageal squamous cell carcinoma ( 132 , 133 ) and malaria ( 134 ). Romidepsin is also used in C57BL/6 (0.03mg/kg twice a week) ( 135 , 136 ) and BALB/C(1mg/kg/2days) ( 137 ) mice for cancer treatment. Therefore, FT895, quisinostat and romidepsin are tolerable and safe in vivo .…”

Section: Hdac11 Inhibitorsmentioning

confidence: 99%

HDAC11, an emerging therapeutic target for metabolic disorders

et al. 2022

View full text Add to dashboard Cite

Histone deacetylase 11 (HDAC11) is the only member of the class IV HDAC, and the latest member identified. It is highly expressed in brain, heart, kidney and some other organs, and located in mitochondria, cytoplasm and nuclei, depending on the tissue and cell types. Although studies in HDAC11 total knockout mice suggest its dispensable features for tissue development and life, it participates in diverse pathophysiological processes, such as DNA replication, tumor growth, immune regulation, oxidant stress injury and neurological function of cocaine. Recent studies have shown that HDAC11 is also critically involved in the pathogenesis of some metabolic diseases, including obesity, diabetes and complications of diabetes. In this review, we summarize the recent progress on the role and mechanism of HDAC11 in the regulation of metabolic disorders, with the focus on its regulation on adipogenesis, lipid metabolism, metabolic inflammation, glucose tolerance, immune responses and energy consumption. We also discuss the property and selectivity of HDAC11 inhibitors and their applications in a variety of in vitro and in vivo models of metabolic disorders. Given that pharmacological and genetic inhibition of HDAC11 exerts a beneficial effect on various metabolic disorders, HDAC11 may be a potential therapeutic target to treat chronic metabolic diseases.

show abstract